
Monica Wallter
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 737 070922
Email: monica.wallter@liddspharma.com

Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
Monica Wallter
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 737 070922
Email: monica.wallter@liddspharma.com
Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
We are using cookies to give you the best experience on our website.
You can find out more about which cookies we are using or switch them off in settings.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
More information about our Cookie Policy
More information about our Privacy Policy